Cipla Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Cipla Ltd. on BSE

Load latest

Cipla Ltd.

13 May 2025

1510.00

0.51%

Annual Report

Annual report for Cipla Ltd. for FY-2025

None

pdf

Cipla Ltd.

30 Apr 2025

1510.00

0.51%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Management of the Company will be holding one-on-one meetings or group meetings with investors in Singapore as part of a Non-Deal Roadshow organised by ICICI Securities Limited from 19th May, 2025 to 21th May, 2025.

pdf

Cipla Ltd.

30 Apr 2025

1510.00

0.51%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein mention the schedule of Analyst / Institutional Investor Meeting with the Company

pdf

Cipla Ltd.

29 Apr 2025

1510.00

0.51%

Corp. Note

Cipla Ltd - 500087 - Format of the Initial Disclosure to be made by an entity …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyCipla Ltd 2CIN NO.L24239MH1935PLC002380 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AAA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Rajendra Chopra Designation: Company Secretary and Compliance Officer EmailId: cosecretary@cipla.com Name of the Chief Financial Officer: Ashish Adukia Designation: Global Chief Financial Officer EmailId: cosecretary@cipla.com Date: 29/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Cipla Ltd.

24 Apr 2025, 06:40PM

1510.00

0.51%

Company Update

Cipla Ltd - 500087 - Intimation Under Regulation 30 Read With Schedule III Of The SEBI …

BSE India

Please find enclosed disclosure on ESG rating.

pdf

Cipla Ltd.

17 Apr 2025

1510.00

0.51%

Company Update

Cipla Ltd - 500087 - Update On USFDA Inspection At Manufacturing Facility Of Medispray In Kundaim, …

BSE India

Update on USFDA inspection at manufacturing facility of Medispray in Kundaim, Goa, India

pdf

Cipla Ltd.

17 Apr 2025

1510.00

0.51%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 13th May, 2025.

pdf

Cipla Ltd.

17 Apr 2025

1510.00

0.51%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 we hereby notify that the Operations and Administrative Committee of the Company on 17th April, 2025 has allotted 23,282 fully paid up equity shares of INR 2/- each pursuant to exercise of employee stock options under the Employee Stock Option Scheme 2013-A of the Company.

pdf

Cipla Ltd.

16 Apr 2025

1510.00

0.51%

Company Update

Cipla Ltd - 500087 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate under Regulation 74(5) of SEBI (DP) Regulation, 2018

pdf

Cipla Ltd.

11 Apr 2025

1510.00

0.51%

Company Update

Cipla Ltd - 500087 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure …

BSE India

Company has received final approval from USFDA for ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial (''Protein-bound Paclitaxel'') on 10th April, 2025

pdf

Is Cipla Ltd. worth buying?

612 Votes:

Buy 75.98%

Sell 13.89%

Hold 10.13%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf